| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| TAX PREPARATION FEES | 4,934 | 0 | 0 | 4,934 |
| Dissolution Name | Dissolution Address | Explanation | Dissolution Amount |
|---|---|---|---|
| AUTISM SCIENCE FOUNDATION |
106 WEST 32ND 182 NEW YORK,NY10001 |
CLINICAL RESEARCH ASSOCIATES, LLC'S REMAINING ASSETS CONSISTED SOLELY OF CASH TOTALING $158,739, WHICH WAS TRANSFERRED TO THE AUTISM SCIENCE FOUNDATION, A 501(C)(3) PUBLIC CHARITY, ON DECEMBER 31, 2025 NO OTHER ASSETS WERE AVAILABLE FOR DISTRIBUTION. | 158,739 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| PART I, LINE 23 & PART II, LINES 8 & 15 | ASSETS WRITE-OFF | PATENT AMORTIZATION EXPENSEDATE ACQUIRED 1/1/2014PATENT ORIGINAL VALUE $1,000,000 2025 AMORTIZATION $(49,310) DEDUCTION IN PRIOR YEARS $(845,310) ------------TOTAL AMORTIZATION $(894,620) ------------LOSS ON DISPOSAL OF ASSETS $(105,380) ------------PATENT NET VALUE $0INVENTORY WRITE-OFFINVENTORY AS OF 07/31/25 $629,078INVENTORY WRITE-OFF $(629,078) ------------INVENTORY NET VALUE $0STATEMENT REGARDING ASSETS WRITE-OFFAS OF AUGUST 1, 2025, THE REMAINING NET BOOK VALUE OF THE PATENT WAS $105,380 AND THE ASSOCIATED INVENTORY BALANCE WAS $629,078. MANAGEMENT DETERMINED THAT NEITHER THE PATENT, WHICH HAD BEEN REPORTED AS AN INTANGIBLE ASSET (R&D) ON FORM 990-PF, NOR THE RELATED INVENTORY HAD ANY REMAINING BOOK VALUE OR REALIZABLE FAIR MARKET VALUE. BASED ON THE HIGHLY SPECIALIZED NATURE OF THE DRUG, THE ABSENCE OF AN ACTIVE MARKET, THE LACK OF INTERESTED BUYERS, AND THE EXPECTATION THAT NO FUTURE ECONOMIC BENEFITS WOULD BE REALIZED FROM THESE ASSETS, THE CARRYING AMOUNTS WERE WRITTEN DOWN TO ZERO, RESULTING IN A LOSS ON DISPOSAL OF ASSETS OF $734,458. |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| COOLEY LLP | 244,760 | 0 | 0 | 265,056 |
| FOX ROTHSCHILD LLP | 7,878 | 0 | 0 | 7,878 |
| LOEB, BLOCK & PARTNERS LLP | 1,428 | 0 | 0 | 1,428 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| INTANGIBLE ASSET (R&D) | 154,690 | 0 | 0 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| DIRECT PROGRAM | 293,227 | 0 | 0 | 308,536 |
| PHARMACEUTICAL RESEARCH | 205,767 | 0 | 0 | 366,943 |
| CLINICAL TRIAL INSURANCE | 16,320 | 0 | 0 | 16,320 |
| INFORMATION TECHNOLOGY | 8,147 | 0 | 0 | 8,591 |
| ADMINISTRATIVE | 40,172 | 2,664 | 2,664 | 34,845 |
| EMPLOYEE DEVELOPMENT | 1,761 | 0 | 0 | 1,873 |
| PATENT AMORTIZATION | 49,310 | 0 | 0 | 0 |
| LOSS ON DISPOSAL OF ASSETS | 734,458 | 0 | 0 | 0 |
| Description | Beginning of Year - Book Value | End of Year - Book Value |
|---|---|---|
| DUE TO THE SIMONS FOUNDATION | 51,900 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| HUMAN RESOURCES CONSULTING | 1,090 | 0 | 0 | 1,264 |
| MISC. PROFESSIONAL SERVICES | 306 | 0 | 0 | 306 |